Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema
Abstract APOLLON (NCT02924311) was a prospective observational study to evaluate the effectiveness of intravitreal aflibercept (IVT-AFL) treatment of diabetic macular edema (DME) over 24 months in routine clinical practice in France. The primary endpoint was mean change from baseline in best-correct...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-22838-1 |
| _version_ | 1811197975979884544 |
|---|---|
| author | Jean-François Korobelnik Vincent Daien Céline Faure Ramin Tadayoni Audrey Giocanti-Aurégan Corinne Dot Laurent Kodjikian Pascale Massin the APOLLON study investigators |
| author_facet | Jean-François Korobelnik Vincent Daien Céline Faure Ramin Tadayoni Audrey Giocanti-Aurégan Corinne Dot Laurent Kodjikian Pascale Massin the APOLLON study investigators |
| author_sort | Jean-François Korobelnik |
| collection | DOAJ |
| description | Abstract APOLLON (NCT02924311) was a prospective observational study to evaluate the effectiveness of intravitreal aflibercept (IVT-AFL) treatment of diabetic macular edema (DME) over 24 months in routine clinical practice in France. The primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study letters) by 12 months, and safety was monitored throughout the study. Of 402 patients enrolled across 61 participating clinics and hospitals in France, 168 patients were followed for at least 24 months and included in the effectiveness analyses (79 treatment-naïve and 89 previously treated). After 24 months of IVT-AFL treatment, the mean (± standard deviation [SD]) change in BCVA from baseline was + 6.5 (± 10.7) letters in treatment-naïve patients (p < 0.001) and + 1.6 (± 17.0) letters in previously treated patients (p = 0.415) from a baseline of 63.8 (± 13.6) and 60.5 (± 16.5) letters. The mean number of IVT-AFL treatments over 24 months was 11.3 (± 4.9) and 11.9 (± 4.7) for treatment-naïve and previously treated patients. This final analysis of the APOLLON study indicated that following 24 months of IVT-AFL treatment in routine clinical practice in France, treatment-naïve patients with DME achieved significant gains in visual acuity and previously treated patients maintained prior visual acuity gains. Trial registration number: NCT02924311. |
| first_indexed | 2024-04-12T01:23:29Z |
| format | Article |
| id | doaj.art-be073d9391394e1fba26c7c671e0407f |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-12T01:23:29Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-be073d9391394e1fba26c7c671e0407f2022-12-22T03:53:43ZengNature PortfolioScientific Reports2045-23222022-10-011211910.1038/s41598-022-22838-1Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edemaJean-François Korobelnik0Vincent Daien1Céline Faure2Ramin Tadayoni3Audrey Giocanti-Aurégan4Corinne Dot5Laurent Kodjikian6Pascale Massin7the APOLLON study investigatorsService d’Ophtalmologie, Hôpital Pellegrin, CHU de Bordeaux, Place Amélie Raba LéonHôpital Gui De ChauliacHôpital Privé Saint Martin, Ramsay Générale de SantéHôpital Lariboisière, Université de Paris, Hôpital I, AP-HP, Hôpital Fondation RothschildAvicenne, AP-HP, Université Paris 13, DHU Vision Et HandicapsHIA DesgenettesDepartment of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de LyonCUDC, Hôpital LariboisièreAbstract APOLLON (NCT02924311) was a prospective observational study to evaluate the effectiveness of intravitreal aflibercept (IVT-AFL) treatment of diabetic macular edema (DME) over 24 months in routine clinical practice in France. The primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study letters) by 12 months, and safety was monitored throughout the study. Of 402 patients enrolled across 61 participating clinics and hospitals in France, 168 patients were followed for at least 24 months and included in the effectiveness analyses (79 treatment-naïve and 89 previously treated). After 24 months of IVT-AFL treatment, the mean (± standard deviation [SD]) change in BCVA from baseline was + 6.5 (± 10.7) letters in treatment-naïve patients (p < 0.001) and + 1.6 (± 17.0) letters in previously treated patients (p = 0.415) from a baseline of 63.8 (± 13.6) and 60.5 (± 16.5) letters. The mean number of IVT-AFL treatments over 24 months was 11.3 (± 4.9) and 11.9 (± 4.7) for treatment-naïve and previously treated patients. This final analysis of the APOLLON study indicated that following 24 months of IVT-AFL treatment in routine clinical practice in France, treatment-naïve patients with DME achieved significant gains in visual acuity and previously treated patients maintained prior visual acuity gains. Trial registration number: NCT02924311.https://doi.org/10.1038/s41598-022-22838-1 |
| spellingShingle | Jean-François Korobelnik Vincent Daien Céline Faure Ramin Tadayoni Audrey Giocanti-Aurégan Corinne Dot Laurent Kodjikian Pascale Massin the APOLLON study investigators Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema Scientific Reports |
| title | Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema |
| title_full | Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema |
| title_fullStr | Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema |
| title_full_unstemmed | Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema |
| title_short | Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema |
| title_sort | two year outcomes of the apollon observational study of intravitreal aflibercept monotherapy in france in patients with diabetic macular edema |
| url | https://doi.org/10.1038/s41598-022-22838-1 |
| work_keys_str_mv | AT jeanfrancoiskorobelnik twoyearoutcomesoftheapollonobservationalstudyofintravitrealafliberceptmonotherapyinfranceinpatientswithdiabeticmacularedema AT vincentdaien twoyearoutcomesoftheapollonobservationalstudyofintravitrealafliberceptmonotherapyinfranceinpatientswithdiabeticmacularedema AT celinefaure twoyearoutcomesoftheapollonobservationalstudyofintravitrealafliberceptmonotherapyinfranceinpatientswithdiabeticmacularedema AT ramintadayoni twoyearoutcomesoftheapollonobservationalstudyofintravitrealafliberceptmonotherapyinfranceinpatientswithdiabeticmacularedema AT audreygiocantiauregan twoyearoutcomesoftheapollonobservationalstudyofintravitrealafliberceptmonotherapyinfranceinpatientswithdiabeticmacularedema AT corinnedot twoyearoutcomesoftheapollonobservationalstudyofintravitrealafliberceptmonotherapyinfranceinpatientswithdiabeticmacularedema AT laurentkodjikian twoyearoutcomesoftheapollonobservationalstudyofintravitrealafliberceptmonotherapyinfranceinpatientswithdiabeticmacularedema AT pascalemassin twoyearoutcomesoftheapollonobservationalstudyofintravitrealafliberceptmonotherapyinfranceinpatientswithdiabeticmacularedema AT theapollonstudyinvestigators twoyearoutcomesoftheapollonobservationalstudyofintravitrealafliberceptmonotherapyinfranceinpatientswithdiabeticmacularedema |